Marcum Wealth LLC raised its position in Pfizer Inc. (NYSE:PFE) by 0.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,245 shares of the biopharmaceutical company’s stock after buying an additional 261 shares during the quarter. Marcum Wealth LLC’s holdings in Pfizer were worth $1,733,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently added to or reduced their stakes in the company. Wakefield Asset Management LLLP purchased a new stake in shares of Pfizer during the second quarter worth approximately $1,458,000. National Asset Management Inc. raised its stake in shares of Pfizer by 38.7% during the second quarter. National Asset Management Inc. now owns 334,418 shares of the biopharmaceutical company’s stock worth $13,075,000 after purchasing an additional 93,382 shares during the last quarter. One Charles Private Wealth Services LLC purchased a new stake in shares of Pfizer during the second quarter worth approximately $280,000. TRUE Private Wealth Advisors raised its stake in shares of Pfizer by 4.4% during the second quarter. TRUE Private Wealth Advisors now owns 129,475 shares of the biopharmaceutical company’s stock worth $5,070,000 after purchasing an additional 5,453 shares during the last quarter. Finally, Select Asset Management & Trust raised its stake in shares of Pfizer by 22.9% during the second quarter. Select Asset Management & Trust now owns 141,112 shares of the biopharmaceutical company’s stock worth $5,526,000 after purchasing an additional 26,301 shares during the last quarter. Institutional investors and hedge funds own 64.93% of the company’s stock.
In other news, SVP Jennifer B. Damico sold 1,661 shares of the business’s stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $48.30, for a total value of $80,226.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the completion of the transaction, the senior vice president now directly owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.
Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.10. The company had revenue of $18.98 billion for the quarter, compared to analyst estimates of $17.54 billion. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. During the same quarter in the prior year, the company earned $0.78 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 4.12 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a yield of 3.47%. Pfizer’s dividend payout ratio (DPR) is 70.27%.
Several research firms have recently commented on PFE. Truist began coverage on Pfizer in a research note on Tuesday, July 27th. They set a “buy” rating and a $43.00 price target for the company. SVB Leerink reiterated a “hold” rating and issued a $49.00 price objective on shares of Pfizer in a research report on Tuesday. Berenberg Bank reiterated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research report on Tuesday, June 15th. The Goldman Sachs Group set a $48.00 price objective on Pfizer in a research report on Thursday, July 29th. Finally, JPMorgan Chase & Co. increased their price objective on Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a research report on Monday. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $42.77.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.